FATE THERAPEUTICS INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
FATE THERAPEUTICS INC (FATE) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-11-12
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was -$62.00K.
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $164.00K.
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $682.00K, a 92.07% decline from fiscal 2021.
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $8.60M, a 82.55% decline from fiscal 2020.
- FATE THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $49.29M, a 379030.77% increase from fiscal 2019.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$62.00K derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-K · filed 2024-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $62.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $62.00K 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $164.00K derived: sum of 2 quarters · filed 2024-02-26 | $682.00K 10-K · filed 2024-02-26 | |
| 2022-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $682.00K 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $518.00K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $7.05M derived: sum of 2 quarters · filed 2023-02-28 | $7.16M derived: sum of 3 quarters · filed 2023-02-28 | $8.60M 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $102.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.55M 10-Q · filed 2022-11-03 | $2.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.55M 10-Q · filed 2022-08-03 | $2.73M derived: sum of 3 quarters · filed 2023-02-28 | $2.61M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.44M 10-Q · filed 2022-05-04 | $2.63M derived: sum of 2 quarters · filed 2023-02-28 | $2.50M derived: sum of 3 quarters · filed 2023-02-28 | $2.92M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.06M derived: sum of 2 quarters · filed 2023-02-28 | $1.48M derived: sum of 3 quarters · filed 2023-02-28 | $49.29M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $291.00K derived: sum of 2 quarters · filed 2021-11-04 | $48.10M 10-Q · filed 2021-11-04 | $40.41M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $48.23M 10-Q · filed 2021-08-04 | $40.53M derived: sum of 3 quarters · filed 2022-02-28 | $40.53M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $47.81M 10-Q · filed 2021-05-05 | $40.12M derived: sum of 2 quarters · filed 2022-02-28 | $40.12M derived: sum of 3 quarters · filed 2022-02-28 | $40.12M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$7.69M derived: sum of 2 quarters · filed 2022-02-28 | -$7.69M derived: sum of 3 quarters · filed 2022-02-28 | $13.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $7.71M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $7.71M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $7.71M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |